Esteve Pharmaceuticals
As of the edition of 20 October 2026, Esteve Pharmaceuticals runs 9 drugs, 9 of them marketed; it is on route A at 0 targets and on route B at 13 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 4 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 9 |
| Total | 9 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Ketoconazole | none listed | 2 |
| Vandetanib | none listed | 10 |
| Cetirizine | none listed | 3 |
| Mecasermin | Ended 2017 (computed from the first US licence) | 2 |
| Metyrapone | none listed | 1 |
| Mitotane | none listed | 1 |
| Ziconotide | none listed | 1 |
| Mifamurtide acid | none listed | 0 |
| Ziconotide acetate | none listed | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 13 targets.
All 13 rows on route A or B
In the product13 company-target rows on route A or B; 10 are not shown here, and no score is.
See all 13 targets where Esteve Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.